Newsroom

IRVINE, Calif.--(BUSINESS WIRE)--Boot Barn Holdings, Inc. (NYSE: BOOT) (the “Company,” “we,” “us,” and “our”) today announced preliminary results for the third quarter of fiscal year 2026 ended December 27, 2025 in advance of its participation in the ICR Conference on Monday, January 12, 2026. A Supplemental Financial Presentation is available at investor.bootbarn.com. Preliminary Results for the Third Quarter of Fiscal Year 2026 For the third quarter ended December 27, 2025, the Company expect...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors a class action on behalf of purchasers of securities and sellers of put options of Sprouts Farmers Market, Inc. (NASDAQ: SFM) between June 4, 2025 and October 29, 2025. Sprouts describes itself as a “specialty grocery store chain that operates throughout the US, with more than 450 stores across 24 states.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3...

NEW YORK--(BUSINESS WIRE)--DWS Municipal Income Trust (KTF) (the “Fund”) announced today its regular January monthly distribution. Details are as follows: Declaration – 01/09/2026 Ex-Date – 01/21/2026 Record – 01/21/2026 Payable – 01/30/2026   Fund   Ticker     Distribution Per Share   Prior Distribution Per Share DWS Municipal Income Trust KTF $0.0610 $0.0610 The Fund intends to distribute all or substantially all of its net investment income each year through its regular monthly distributions...

LAS VEGAS--(BUSINESS WIRE)--Wynn Resorts announced today that Craig Jeffrey Fullalove will succeed Julie Cameron-Doe as Chief Financial Officer of Wynn Resorts, Limited. Ms. Cameron-Doe has elected to retire in mid-2026 but will continue to serve as a consultant to the Company and as a Non-Executive Director of Wynn Macau, Limited. Mr. Fullalove is currently the Chief Financial Officer and Chief Administrative Officer of Wynn Resorts’ Macau operations, and its Hong Kong-listed entity, Wynn Maca...

PEMBROKE, Bermudas--(BUSINESS WIRE)--Gold Reserve Ltd. (TSX.V: GRZ) (BSX: GRZ.BH) (OTCQX: GDRZF) (“Gold Reserve” o la “Empresa”) informó que ayer presentó su escrito inicial de apelación ante el Tribunal de Apelaciones del Tercer Circuito de Estados Unidos (el “Tercer Circuito”). La apelación se enmarca en la propuesta de venta judicial de las acciones de PDVH a Elliott/Amber Energy. En su apelación, la Empresa sostiene, entre otros argumentos, que la orden del Tribunal de Distrito de Estados U...

COLUMBUS, Ohio--(BUSINESS WIRE)--Mettler-Toledo International Inc. (NYSE: MTD) announced it will release its fourth quarter 2025 financial results after the market close on Thursday, February 5, 2026. The Company will host a conference call the following morning at 8:30 a.m. Eastern Time to discuss the results. To listen to the live audio webcast of the call, visit Events and Presentations on the Investor section of the Company’s website, investor.mt.com. METTLER TOLEDO (NYSE: MTD) is a leading...

ベルギー・ヘント--(BUSINESS WIRE)--（ビジネスワイヤ） -- 炎症性疾患およびがん免疫におけるマイクロバイオームベース治療薬の開発のパイオニアである、臨床段階のバイオ医薬品企業のMRMヘルスは、主要プログラムMH002に関する治験薬（IND）申請が米国食品医薬品局（FDA）により承認されたことを発表しました。これにより、軽度から中等度の潰瘍性大腸炎患者を対象としたSTARFISH-UC後期第2相臨床試験を開始することが可能となり、炎症性腸疾患（IBD）に対する次世代治療法の開発において重要な進展を遂げることができました。 STARFISH-UC後期第II相試験について STARFISH-UC試験は、MH002の前期第II相試験で事前に観察された有望な有効性シグナルと良好な安全性プロファイルを確認することを目的とする無作為化二重盲検プラセボ対照試験です。合理的に設計された、生きた微生物コンソーシアムであるMH002は、特徴がはっきりした6つの共生菌株の相乗効果を生み出す組み合わせを通じて疾患特異的メカニズムを標的とする、最も先進的な腸内細菌製剤（LBP）です。本試験（...

GAND, Belgio--(BUSINESS WIRE)--MRM Health NV, un'azienda biofarmaceutica di fase clinica all'avanguardia nella terapia basata sul microbioma per le malattie infiammatorie e l'immuno-oncologia, ha annunciato oggi che la Food and Drug Administration (FDA) statunitense ha approvato la sua domanda di autorizzazione all'uso sperimentale di un nuovo farmaco (IND) per il suo programma principale MH002. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale...

GHENT, Bélgica--(BUSINESS WIRE)--MRM Health NV, una empresa biofarmacéutica en fase clínica pionera en terapias basadas en el microbioma para enfermedades inflamatorias e inmunooncología, anuncia que la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) ha concedido la autorización a su solicitud de nuevo fármaco en investigación (IND, por sus siglas en inglés) para MH002, su programa principal. Esta autorización abre la puerta al inicio del ensayo...

GHENT, Bélgica--(BUSINESS WIRE)--A MRM Health NV, uma empresa biofarmacêutica em fase clínica, pioneira em terapêuticas baseadas no microbioma para doenças inflamatórias e imuno-oncologia, anunciou hoje que a Administração de Alimentos e Medicamentos dos Estados Unidos (FDA) concedeu a aprovação do seu pedido de Investigação de Novo Medicamento (IND) para o seu programa principal MH002. Isso permite o início do ensaio clínico STARFISH-UC Fase 2b em pacientes com colite ulcerativa leve a moderad...